Loading...
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma
The MEK inhibitor MEK162 is the first targeted therapy agent with clinical activity in patients whose melanomas harbor NRAS mutations; however, median PFS is 3.7 months, suggesting the rapid onset of resistance in the majority of patients. Here we show that treatment of NRAS-mutant melanoma cell lin...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4211982/ https://ncbi.nlm.nih.gov/pubmed/25130256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12303 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|